RichardDCarvajalMD

PubMed

• Dose Individualization for Phase I Cancer Trials With Broadened Eligibility.
  Rebecca B Silva, Bin Cheng, Richard D Carvajal, Shing M Lee
  Statistics in Medicine. 2024-12-20
• Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
  Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, Phil F Cheng, Isaac F Hughes
  European Journal of Cancer. 2024-11-30
• Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.
  Rino S Seedor, Andrew E Aplin, Corine Bertolotto, Richard D Carvajal, Nigel Deacon
  Pigment Cell & Melanoma Research. 2024-10-09

Journal Articles

• Clinical Trial Designs for Rare Diseases: Studies Developed and Discussed by the International Rare Cancers Initiative  
  Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher..., Eur J Cancer, 1/1/2015
• Treatments for Noncutaneous Melanoma  
  Khalil DN, Carvajal RD, Hematol Oncol Clin North Am, 1/1/2014
• Selecting Patients for KIT Inhibition in Melanoma  
  Carvajal R, Hamid O, Antonescu C, Methods Mol Biol., 1/1/2014
• GNAQ and GNA11 Mutations in Uveal Melanoma  
  Shoushtari AN, Carvajal RD, Melanoma Res, 1/1/2014
• Surveillance Options for Patients with Uveal Melanoma following Definitive Management  
  Francis JH, Patel SP, Gombos DS, Carvajal RD, Am Soc Clin Oncol Educ Book, 1/1/2013
• What Does the Future Hold for Uveal Melanoma, a Historically Untreatable Disease?  
  Shoushtari AN, Carvajal RD, Clin Invest, 1/1/2013
• Ipilimumab for Patients with Advanced Mucosal Melanoma  
  Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwa..., Oncologist, 1/1/2013
• Selumetinib Induced "Dropped Head Syndrome: Report of Three Cases  
  Chen X, Schwartz GK, DeAngelis LM, Kaley T, Carvajal RD, Neurology, 1/30/2012
• A New Era for the Management of Metastatic Melanoma  
  Koneru M, Carvajal RD, of Dermatology, 1/1/2012
• Therapeutic Implications of KIT in Melanoma  
  Postow M, Carvajal RD, The Cancer Journal: The Journal of Principles & Practice of Oncology, 1/1/2012
• Ipilimumab for Metastatic Melanoma  
  Ozao-Choy J, Carvajal RD, Hamid O, Drugs of Today, 1/1/2012
• GSK-1120212, a MEK1/MEK2 Inhibitor for the Potential Oral Treatment of Cancer  
  Postow M, Carvajal RD, Thomson Reuters' Drug Profiles, 1/1/2012
• Ipilimumab Induced Colitis on FDG PET/CT  
  Lyall A, Vargas A, Carvajal RD, Ulaner G, Clin Nucl Med, 1/1/2012
• Characterization of Computed Tomography Scan Abnormalities in Patients with Biopsy-proven Hepatic Metastases from Uveal Melanoma  
  Patel M, Winston CB, Marr BP, Carvajal RD, Schwartz GK, Wolchok J, Busam K, Abramson DH, Archives of ophthalmology, 1/1/2011
• Treatment of Metastatic Melanoma: A New World Opens  
  Smyth, EC, Carvajal RD, The Skin Cancer Foundation Journal, 1/1/2011
• Targeting KIT for the Treatment of Advanced Melanoma  
  Carvajal, RD, The Melanoma Letter, 1/1/2011
• Radiotherapy after Surgical Resection for Head and Neck Mucosal Melanoma  
  Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, Zelefsky MJ, Wolchok JD, Carvajal RD, Chapman PB, Wong RJ, Shaha AR, Kraus DH, Shah JP, Lee NY, American Journal of Clinical Oncology, 1/1/2010
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Cyclin-dependent Kinase Inhibitor AZD5438 When Administered at Intermittent and Continuous Dosi...  
  Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Sha..., Ann Oncol, 1/1/2010
• Possible Role of Edotecarin, a Novel Topoisomerase I Inhibitor, in Therapy-related Myelodysplastic Syndrome  
  Carvajal R, Ilson DH, Noy A, Leukemia and Lymphoma, 1/1/2007
• Aurora Kinases: New Targets for Cancer Therapy  
  Carvajal R, Tse A, Schwartz GK, Clinical Cancer Research, 1/1/2006
• Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors  
  Carvajal R, Meyers P, Hematology/Oncology Clinics of North America, 1/1/2005
• Overexpression of DDX43 mediates MEK-Inhibitor Resistance through RAS up-regulation in Uveal Melanoma Cells  
  Ambrosini G, Khanin R, Carvajal RD, Schwartz GK, Mol Cancer Ther, 1/4./2014
• The Cyclin-dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Phase I Clinical Trial  
  Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK, Clin Cancer Res, 1/28/2012
• Atypical Melanocytic Proliferations and New Primary Melanomas in Advanced Melanoma Patients Undergoing Selective BRAF Inhibition  
  Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long G, McArthur G, Scherag A, ..., J Clin Onc, 1/21/2012
• Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer  
  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake..., N Engl J Med, 1/2./2012
• Join now to see all

Books/Book Chapters

• Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies 
  Chapter: Surveillance for Early Detection of Metastatic Ocular Melanoma following Definitive Local Therapy 
  Page 193.0 - 209.0Francis JH, Kivela T, Carvajal RDEditors: Murray TG, Boldt HC.Future Medicine, London, UK2014
• Textbook of Uncommon Cancers 
  Chapter: Unusual Melanomas 
  Page 685.0 - 690.0Hamid O, Carvajal RD, Morton DL, Faries MEditors: Raghavan D, Blanke CD, Johnson DH, Moots PL, Reaman GH, Rose PG, Sekeres MA.John Wiley & Sons, Inc, Hoboken, NJEdition 4th,2012
• Dx/Rx: Melanoma. Massachusetts 
  Carvajal RDJones and Bartlett Publishers2010
• Cancer Management: A Multidisciplinary Approach 
  Brady MS, Kaushal A, Ko C, Carvajal RDEditors: Haller DG, Wagman LD, Camphausen KA, Hoskins WJ.PRR IncEdition 12th,2013
• Join now to see all

Abstracts/Posters

• Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)
  Carvajal RD, Annual Meeting of the American Society of Clinical Oncology Melanoma Oral Abstract Session, Chicago, Illinois, 1/1/2013
• Rationale, Study Design and Accrual Status of a Randomized Phase II Study of AZD6244 (MEK Inhibitor) vs Temozolomide in Advanced Uveal Melanoma
  Carvajal RD, Macula, New York, New York, 1/1/2012
• A Randomized Phase II Trial of Temozolomide versus AZD6244 in Patients with Metastatic Uveal Melanoma
  Carvajal RD, Cancer Therapy Evaluation Program Early Drug Development Meeting, Bethesda, Maryland, 1/1/2011
• Rationale, Study Design and Accrual Status of a Randomized Phase II Study of AZD6244 versus Temozolomide in Advanced Uveal Melanoma
  Carvajal RD, International Society of Ocular Oncology Biennial Meeting, Buenos Aires, Argentina, 1/1/2011
• A Phase II Study of Imatinib Mesylate (IM) For Patients with Advanced Melanoma Harboring Somatic Alterations of KIT
  Carvajal RD, Annual Meeting of the American Society of Clinical Oncology Clinical Science Symposium, Chicago, Illinois, 1/1/2009
• Join now to see all

Lectures

• Targeted Therapy for Melanoma 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Uveal Melanoma as a Model for Targeted Therapy 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Building Bridges: A Fast(er) Track to the Bedside 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Vision for Experimental Therapeutics at CUMC 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Targeted Therapy for Uveal Melanoma: Biology, Clinical Trials & Challenges 
  Silver Spring, MD - 1/1/2014
• The Early Drug Development Program at MSKCC 
  Memorial Sloan Kettering Cancer Center, 2014; Memorial Hospital, New York, New York, 2014 - 1/1/2014
• Targeted Agents & Immunotherapy for Melanoma 
  Providence, Rhode Island - 1/1/2014
• How to Run a Phase I Clinic: The Early Drug Development Program at MSKCC 
  New York, New York - 1/1/2014
• The New Science of Targeted Therapy: FDA's Viewpoint on Companion Diagnostics for Targeted Studies and Marker Trials 
  New York, New York - 1/1/2014
• GNAQ/11 Mutations in Melanoma: Opportunities for Drug Development 
  New York, New York - 1/1/2014
• Pathway Targeted Therapy for Melanoma 
  New York, New York - 1/1/2014
• Rare Melanomas as a Model for Targeted Therapy 
  Memorial Sloan Kettering Cancer Center, New York, New York - 1/1/2014
• Ocular & Mucosal Melanoma: New Directions 
  Rutgers Cancer Institute of New Jersey, New Brunswick, NJ - 1/1/2014
• Harnessing the Immune System for the Treatment of Melanoma 
  Culver City, California - 1/1/2014
• Rationale for Systemic Therapy of Uveal Melanoma and Review of Current and Future Clinical Trials for Uveal Melanoma 
  Chicago, Illinois - 1/1/2013
• Systemic Therapy for Uveal Melanoma 
  Philadelphia, Pennsylvania - 1/1/2013
• Challenges for the Development of Therapy Trials 
  Philadelphia, Pennsylvania - 1/1/2013
• Targeted Therapy: Ongoing Trials in Uveal Melanoma 
  Philadelphia, Pennsylvania - 1/1/2013
• Gq/11 Mutations in Melanoma: Implications for Drug Development 
  Memorial Sloan Kettering Cancer Center, New York, New York - 1/1/2013
• Melanoma 
  Memorial Sloan Kettering Cancer Center, 2014; Memorial Hospital, New York, New York, 2013 - 1/1/2013
• Melanoma 101 
  Memorial Sloan Kettering Cancer Center - 1/1/2013
• Florida Society of Dermatology & Dermatologic Surgery (FSDDS) 2012 Annual Meeting 
  Florida Society of Dermatology & Dermatologic Surgery, Orlando, Florida - 5/25/2012
• Ipilimumab: Promise and Pitfalls 
  Boston, Massachusetts - 1/1/2012
• Targeting GNAQ/11 for Melanoma Therapy 
  Beijing, China - 1/1/2012
• International Collaborative Efforts in Drug Development for Uveal Melanoma 
  Ft. Lauderdale, Florida - 1/1/2012
• Join now to see all

Other

• Emerging Treatments for Metastatic Melanoma 
  Teleconference, CancerCare
  1/1/2013
• Opportunities and Challenges in the Development of Adjuvant Therapies for Uveal Melanoma 
  Webinar, CureOM
  1/1/2012
• Systemic Treatment Options for Uveal Melanoma 
  Webinar, Melanoma International Foundation
  1/1/2011
• Mucosal melanoma 
  Carvajal RD, Ariyan C, Hamid O
  http://www.uptodate.com/contents/mucosal-melanoma
  UpToDate, Wolters Kluwer Health - 2012-06-11
• Soft Tissue Sarcoma Staging. Medscape Reference 
  Carvajal, RD
  http://emedicine.medscape.com/article/2006584-overview
  1/20/2011
• Soft Tissue Treatment Protocols. Medscape Reference 
  Carvajal, RD
  http://emedicine.medscape.com/article/2007168-overview
  1/1./2012
• Uveal and Conjunctival Melanomas 
  Gragoudas ES, Lane AM, Shih AH, Carvajal RD, UpToDate
  1/3./2013
• Join now to see all